|Videos|July 5, 2023
Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment
The panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts discuss data from the MonumenTAL-3 trial and the evolving roles of talquetamab and other bispecific antibodies in relapsed/refractory multiple myeloma.
Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.
C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
2
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Avutometinib/Defactinib Shows Activity in KRAS Wild-Type Recurrent LGSOC
5